Technological innovation can provide the opportunity to de-escalate treatments. Oncotype DX is considered a valid tool to promote a reduction in the use of chemotherapy in women with a score indicating intermediate-risk early breast cancer. The TAILORx randomized trial showed noninferiority in terms of long-term outcomes of hormone therapy only vs hormone- and chemotherapy (1). Mariotto et al. tested the impact of hypothetical testing of early breast cancer in the real world using SEER-Medicare–based data (2). They showed for the intermediate-risk group a reduction of the burden of chemotherapy in comparison with usual care in the United States.

中文翻译：

---

回复：基于TAILORx试验的Oncotype DX评分一致的系统性乳腺癌治疗的预期货币影响。

技术创新可以为降低治疗水平提供机会。Oncotype DX被认为是一种有效的工具，可以提高女性中度风险的早期乳腺癌评分，从而减少女性的化学疗法使用量。TAILORx随机试验显示，仅在激素治疗与激素和化疗相比，长期疗效方面不逊色（1）。Mariotto等。使用基于SEER-Medicare的数据，对假设的早期乳腺癌测试在现实世界中的影响进行了测试（2）。他们显示，与美国的常规护理相比，中危组的化疗负担有所减轻。